Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Interim Management Statement

13 May 2014 07:00

RNS Number : 8370G
Ark Therapeutics Group PLC
13 May 2014
 



 

Ark Therapeutics Group plc

 

Interim Management Statement and Notice of Annual General Meeting

 

13 May 2014 - Ark Therapeutics Group plc ("Ark" or the "Company") today publishes its interim management statement for the period from 1 January 2014 to date.

 

· On 28 March 2014, we were pleased to announce that the Company had signed heads of terms in connection with the possible acquisition of a revenue-generating and profitable UK-based private company in the healthcare support services sector ("Target").

 

The transaction would be structured by way of an acquisition of the Target by Ark in consideration for the issue of new Ark shares to the shareholders of the Target. Due to its size in relation to Ark, the proposed acquisition of the Target would constitute a 'reverse takeover' for the purposes of the Listing Rules.

 

In response to a request by the Company, the UK Listing Authority suspended the listing of Ark's Premium listed shares on the Main Market of the London Stock Exchange on 28 March 2014 pending publication of the required shareholder documents. Shareholder approval would be required to approve the acquisition of the Target which would be sought at a general meeting to be convened in due course, after which the Company would also expect to seek a lifting of the trading suspension. 

 

The Board will make further announcements in due course.

 

· On 30 April 2014, the Company announced its financial results for the year ended 31 December 2013:

 

· Total revenues and other income for the year ended 31 December 2013 of £0.3m (31 December 2012: £1.9m)

 

· Net assets at 31 December 2013 of £0.9m (31 December 2012: net liabilities of £0.2m)

 

· Cash and short-term deposits of £0.8m (31 December 2012: £1.7m)

 

· Profit for the year after tax was £1.1m (31 December 2012: loss after tax was £2.5m)

 

The Company's Annual General Meeting will be held at 2.30 pm on 30 June 2014 at the offices of Ashurst LLP, Broadwalk House, 5 Appold Street, London EC2A 4HA.

 

 

For further information please contact:

 

Ark Therapeutics Group plc

Tel: +44 (0)203 755 5160

 

Iain G Ross, Non-Executive Chairman

 

David Venables, Non-Executive Director

 

 

 

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding Ark's financial position, business strategy, plans and objectives of management for future operations, and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond Ark's control that could cause the actual results, performance or achievements of Ark to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding Ark's present and future business strategies and the environment in which Ark will operate in the future. These forward-looking statements speak only as at the date of this announcement. Ark expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in Ark's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSGGUWGAUPCGUP
Date   Source Headline
19th May 20087:00 amRNSResearch Update
16th May 20087:00 amRNSInterim Management Statement
24th Apr 20084:57 pmRNSAGM Results
22nd Apr 20087:00 amRNSRegulatory Update
17th Apr 20087:00 amRNSProduct Update
1st Apr 20083:26 pmRNSAnnual Information Update
31st Mar 200812:39 pmRNSTotal Voting Rights
28th Mar 20081:46 pmRNSRe Appointment
20th Mar 20087:00 amRNSBoard Appointment
11th Mar 20087:01 amRNSLaunch of Neuropad
11th Mar 20087:01 amRNSFinal Results
5th Mar 20085:20 pmRNSHolding(s) in Company
13th Feb 20087:00 amRNSManufacturing Update
31st Jan 200810:27 amRNSVoting Rights and Capital
23rd Jan 20084:56 pmRNSNotice of Results
18th Jan 20087:01 amRNSResearch Update
17th Jan 200810:42 amRNSRe: Employee Benefit Trust
11th Jan 200810:33 amRNSDirector/PDMR Shareholding
9th Jan 20084:50 pmRNSResignation of NED
8th Jan 20087:00 amRNSAcquisition
19th Dec 20074:37 pmRNSPrice Monitoring Extension
6th Dec 20075:48 pmRNSHolding(s) in Company
5th Dec 20071:39 pmRNSHolding(s) in Company
5th Dec 200712:41 pmRNSHolding(s) in Company
4th Dec 20075:40 pmRNSBlocklisting Interim Review
4th Dec 20074:56 pmRNSBlocklisting Interim Review
4th Dec 200711:50 amRNSHolding(s) in Company
30th Nov 200712:35 pmRNSDirector/PDMR Shareholding
30th Nov 200712:10 pmRNSVoting Rights and Capital
29th Nov 20072:17 pmRNSResult of EGM
28th Nov 20074:27 pmRNSRe: Placing and Open Offer
6th Nov 20077:01 amRNSPlacing and Open Offer
30th Oct 20075:08 pmRNSHolding(s) in Company
25th Oct 20077:01 amRNSResearch Update
22nd Oct 20071:01 pmRNSHolding(s) in Company
16th Oct 20073:23 pmRNSHolding(s) in Company
10th Oct 20077:01 amRNSRe Agreement
8th Oct 20077:00 amRNSRe Agreement
28th Sep 20073:06 pmRNSVoting Rights and Capital
31st Aug 200710:39 amRNSVoting Rights and Capital
29th Aug 20077:01 amRNSInterim Results
20th Aug 20077:02 amRNSRe: Product Launch
31st Jul 200711:23 amRNSVoting Rights and Capital
26th Jul 20077:01 amRNSResearch Update
24th Jul 200711:18 amRNSNotice of Results
23rd Jul 20077:01 amRNSRe: Cerepro
6th Jul 20077:00 amRNSEPO Grant Stroke Patent
29th Jun 20071:14 pmRNSVoting Rights and Capital
22nd Jun 20074:03 pmRNSHolding(s) in Company
15th Jun 20072:45 pmRNSDirector's Share Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.